#3

FILE NO.A332626-A 067252.0107
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Smith et al.			
Serial No.	:	09/910,186	Examiner	:	TBA
Filed	:	July 20, 2001	Group Art Unit	:	1645
For	:	RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN			

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231

November 19, 2001
Date of Deposit

Rochelle K. Seide
Attorney Name

32,300
PTO Registration No

Rochelle K. Seide
Signature

November 19, 2001
Date of Signature

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply mailed on September 17, 2001, please consider the following amendments and remarks. Applicants submit herewith a Substitute Sequence Listing in paper and computer-readable form.

IN THE SPECIFICATION:

Please delete the Sequence Listing of record and substitute therefor, the Substitute Sequence Listing included herewith in paper and computer form.

REMARKS

The Notice to Comply mailed September 17, 2001 for the above-identified application alleges that the application fails to comply with the requirements of 37 C.F.R. 1.821 through 1.825.

Applicants submit herewith a Substitute Sequence Listing in paper and computer form. I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e), are the same. I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(g), herein does not include new matter.

Applicants do not believe any fee is required for this filing. Nevertheless, the Commissioner is hereby authorized to charge any fees due with this submission not otherwise enclosed herewith to Deposit Account No. 02-4377. Two copies of this paper are enclosed.

A copy of the Notice to Comply is enclosed.

Respectfully submitted,

Rochelle K. Seide

Rochelle K. Seide
PTO Reg. No. 32,300
Attorney for Applicants

Michelle M. LeCointe
Patent Office Reg. No. 46,861
Agent for Applicants

BAKER BOTTS, L.L.P.
30 Rockefeller Plaza
New York, NY 10112
(212) 408-2626

Enclosures

Application No.: 09/910,186

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☒ 7. Other: Additional sequences found

Applicant Must Provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support (SIRA)
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Copy